ÅǸ޴º
¹øÈ£ | ±¸ºÐ | Á¦¸ñ |
---|---|---|
20 | (±¹¿Ü)SCIE | Real-World Experience with Pembrolizumab Treatment in Patients with Heavily Treated Recurrent Gynecologic Malignancies |
19 | (±¹¿Ü)SCIE | Real-World Experience with Pembrolizumab Treatment in Patients with Heavily Treated Recurrent Gynecologic Malignancies |
18 | (±¹¿Ü)SCIE | Real-World Experience with Pembrolizumab Treatment in Patients with Heavily Treated Recurrent Gynecologic Malignancies |
17 | (±¹¿Ü)SCIE | Real-World Experience with Pembrolizumab Treatment in Patients with Heavily Treated Recurrent Gynecologic Malignancies |
16 | (±¹¿Ü)SCIE | Real-World Experience with Pembrolizumab Treatment in Patients with Heavily Treated Recurrent Gynecologic Malignancies |
15 | (±¹¿Ü)SCIE | Real-World Experience with Pembrolizumab Treatment in Patients with Heavily Treated Recurrent Gynecologic Malignancies |
14 | (±¹¿Ü)SCI | Atypical endometriosis is related to a higher recurrence rate |
13 | (±¹¿Ü)SCI | Atypical endometriosis is related to a higher recurrence rate |
12 | (±¹¿Ü)SCI | Atypical endometriosis is related to a higher recurrence rate |
11 | (±¹¿Ü)SCI | Atypical endometriosis is related to a higher recurrence rate |
Copyright ¨Ï chamc, All rights reserved.